PolyPid to Present at the Barclays Global Healthcare Conference

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced